Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Lablanche JM, Leone A, Merkely B, Morais J, Alonso J, Santini M, Eha J, Demil N, Licour M, Tardif JC; CENTAURUS investigators. Lablanche JM, et al. Among authors: alonso j. Arch Cardiovasc Dis. 2010 Mar;103(3):160-9. doi: 10.1016/j.acvd.2010.01.005. Epub 2010 Apr 8. Arch Cardiovasc Dis. 2010. PMID: 20417447 Free article. Clinical Trial.
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Lablanche JM, Danchin N, Farnier M, Tedgui A, Vicaut E, Alonso J, Crean P, Leone A, Morais J, Santini M, Licour M, Farah M, Tardif JC. Lablanche JM, et al. Among authors: alonso j. Arch Cardiovasc Dis. 2008 Jun;101(6):399-406. doi: 10.1016/j.acvd.2008.05.010. Epub 2008 Aug 20. Arch Cardiovasc Dis. 2008. PMID: 18809153 Free article. Clinical Trial.
Plasma Levels of Propionylcarnitine Improved Prediction of Heart Failure and All-Cause Mortality in Patients with Stable Coronary Artery Disease.
Lumpuy-Castillo J, Rupérez FJ, Porto BLS, Cristóbal C, Tarín N, Huelmos AI, Alonso J, Egido J, Mahíllo-Fernández I, López-Bescós L, Tuñón J, Lorenzo Ó. Lumpuy-Castillo J, et al. Among authors: alonso j. Biomolecules. 2024 Dec 29;15(1):27. doi: 10.3390/biom15010027. Biomolecules. 2024. PMID: 39858422 Free PMC article.
Beyond secondary prevention drugs: Added benefit in survival and events of a healthy lifestyle in patients after an acute coronary syndrome.
Rodríguez EC, Kallmeyer A, Tarín N, Cristóbal C, Huelmos A, Lázaro AMP, Aceña Á, Gutiérrez-Landaluce C, González-Lorenzo Ó, Lumpuy-Castillo J, Alonso J, López-Bescós L, Egido J, Lorenzo Ó, Blanco-Colio LM, Tuñón J. Rodríguez EC, et al. Among authors: alonso j. Am J Prev Cardiol. 2024 Dec 22;21:100923. doi: 10.1016/j.ajpc.2024.100923. eCollection 2025 Mar. Am J Prev Cardiol. 2024. PMID: 39834624 Free PMC article.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2024 Dec 23:dkae456. doi: 10.1093/jac/dkae456. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39710424
3,684 results